Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
RIGL Rigel Pharmaceuticals	$19.28 +1.2%	$19.08	$7.48 ▼ $29.82	$344.48M	1.32	208,172 shs	106,830 shs
SNSS Sunesis Pharmaceuticals		$3.53	$1.12 ▼ $11.30	$96.26M	2.27	4.33 million shs	1.20 million shs
VNDA Vanda Pharmaceuticals	$4.25 -1.4%	$4.56	$3.85 ▼ $6.75	$247.84M	0.72	771,349 shs	472,481 shs
ZBIO Zenas Biopharma	$10.02 +0.4%	$0.00	$5.83 ▼ $26.25	$418.83M	N/A	194,838 shs	79,751 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
RIGL Rigel Pharmaceuticals	0.00%	+14.42%	+4.84%	-13.04%	+71.38%
SNSS Sunesis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
VNDA Vanda Pharmaceuticals	0.00%	-1.85%	-7.61%	-3.41%	-6.80%
ZBIO Zenas Biopharma	0.00%	+12.33%	+24.78%	+1,001,999,900.00%	+1,001,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
RIGL Rigel Pharmaceuticals	2.8274 of 5 stars	3.2	1.0	0.0	0.0	3.2	2.5	1.9
SNSS Sunesis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	4.0945 of 5 stars	3.5	1.0	0.0	4.2	1.7	3.3	1.3
ZBIO Zenas Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.80	90.87% Upside
SNSS Sunesis Pharmaceuticals	0.00	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	3.00	Buy	$16.50	288.24% Upside
ZBIO Zenas Biopharma	3.00	Buy	$40.00	299.20% Upside

Current Analyst Ratings Breakdown

Latest SNSS, ZBIO, RIGL, and VNDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/20/2025	ZBIO Zenas Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
3/12/2025	ZBIO Zenas Biopharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
3/6/2025	RIGL Rigel Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $55.00
3/5/2025	RIGL Rigel Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $24.00
3/5/2025	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00
2/18/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $20.00
2/4/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
1/28/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
RIGL Rigel Pharmaceuticals	$179.28M	1.92	N/A	N/A	($1.64) per share	-11.76
SNSS Sunesis Pharmaceuticals	$2.07M	0.00	N/A	N/A	$1.42 per share	0.00
VNDA Vanda Pharmaceuticals	$198.77M	1.25	N/A	N/A	$9.23 per share	0.46
ZBIO Zenas Biopharma	$5M	83.77	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
RIGL Rigel Pharmaceuticals	-$25.09M	$0.94	137.72	18.36	N/A	2.46%	-14.80%	3.03%	5/6/2025 (Estimated)
SNSS Sunesis Pharmaceuticals	-$23.33M	-$2.70	N/A	N/A	N/A	N/A	-179.05%	-72.27%	N/A
VNDA Vanda Pharmaceuticals	-$18.90M	-$0.32	N/A	N/A	N/A	-9.51%	-3.49%	-2.90%	5/6/2025 (Estimated)
ZBIO Zenas Biopharma	N/A	-$3.55	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest SNSS, ZBIO, RIGL, and VNDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	VNDA Vanda Pharmaceuticals	$0.05	N/A	N/A	N/A	$45.13 million	N/A
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	N/A	N/A	N/A	$43.87 million	N/A
3/4/2025	Q4 2024	RIGL Rigel Pharmaceuticals	$0.30	$0.80	+$0.50	$0.80	$57.59 million	$57.60 million
2/13/2025	Q4 2024	VNDA Vanda Pharmaceuticals	-$0.14	-$0.08	+$0.06	-$0.08	$51.00 million	$53.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNSS Sunesis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas Biopharma	$0.05	0.48%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
RIGL Rigel Pharmaceuticals	N/A	1.96	1.87
SNSS Sunesis Pharmaceuticals	N/A	7.74	7.74
VNDA Vanda Pharmaceuticals	N/A	4.39	4.37
ZBIO Zenas Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
RIGL Rigel Pharmaceuticals	66.23%
SNSS Sunesis Pharmaceuticals	28.41%
VNDA Vanda Pharmaceuticals	88.14%
ZBIO Zenas Biopharma	N/A

Insider Ownership

Company	Insider Ownership
RIGL Rigel Pharmaceuticals	9.04%
SNSS Sunesis Pharmaceuticals	4.22%
VNDA Vanda Pharmaceuticals	8.90%
ZBIO Zenas Biopharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.02 million	Optionable
SNSS Sunesis Pharmaceuticals	24	18.09 million	N/A	Optionable
VNDA Vanda Pharmaceuticals	290	58.32 million	53.13 million	Optionable
ZBIO Zenas Biopharma	N/A	41.80 million	N/A	N/A

SNSS, ZBIO, RIGL, and VNDA Headlines

Recent News About These Companies

Head-To-Head Contrast: Zenas Biopharma (ZBIO) vs. Its Competitors

April 27 at 2:29 AM | americanbankingnews.com

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

April 26 at 9:40 AM | globenewswire.com

Reviewing Zenas Biopharma (ZBIO) & The Competition

April 26 at 2:01 AM | americanbankingnews.com

Zenas BioPharma Investors Encouraged to Contact Cohen Milstein to Lead ZBIO IPO Stock Drop Securities Class Action

April 25 at 4:27 PM | globenewswire.com

Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO

April 25 at 4:15 PM | accessnewswire.com

ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

April 25 at 3:45 PM | accessnewswire.com

Contact Levi & Korsinsky by June 16, 2025 Deadline to Join Class Action Against Zenas BioPharma, Inc. (ZBIO)

April 25 at 1:15 PM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ZBIO

April 25 at 12:42 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

April 25 at 12:23 PM | globenewswire.com

Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) Seeking Recovery for Investors - Contact Levi & Korsinsky

April 25 at 10:45 AM | accessnewswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO

April 25 at 10:31 AM | globenewswire.com

Shareholders that lost money on Zenas BioPharma, Inc.(ZBIO) should contact Levi & Korsinsky about pending Class Action - ZBIO

April 25 at 7:25 AM | accessnewswire.com

ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

April 25 at 7:00 AM | accessnewswire.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc.(ZBIO) Shareholders

April 25 at 5:45 AM | prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 16, 2025 in Zenas BioPharma, Inc. Lawsuit - ZBIO

April 25 at 12:30 AM | accessnewswire.com

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm

April 24 at 5:32 PM | prnewswire.com

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 24 at 4:30 PM | accessnewswire.com

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 24 at 4:30 PM | accessnewswire.com

Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO

April 24 at 3:35 PM | accessnewswire.com

Cohen Milstein Seeks Investors Willing to Lead Zenas BioPharma (ZBIO) Securities Fraud Class Action

April 24 at 3:15 PM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSS, ZBIO, RIGL, and VNDA Company Descriptions

Rigel Pharmaceuticals NASDAQ:RIGL

$19.28 +0.22 (+1.15%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$18.90 -0.39 (-2.00%)

As of 04/25/2025 07:38 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Sunesis Pharmaceuticals NASDAQ:SNSS

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.25 -0.06 (-1.39%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$4.24 0.00 (-0.12%)

As of 04/25/2025 04:02 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Zenas Biopharma NASDAQ:ZBIO

$10.02 +0.04 (+0.40%)

As of 04/25/2025 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time